Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
Publishing timestamp: 2023-09-27 10:44:42
Summary
The article discusses the increase in prescriptions for obesity drugs, specifically Ozempic and Wegovy, in the United States. The data shows a 300% increase in prescription volumes for these drugs between early 2020 and the end of 2022. Novo Nordisk's Ozempic accounted for over 65% of total prescriptions and was primarily prescribed off-label for weight loss. The article also mentions supply shortages affecting the manufacturers of these drugs and the potential for other drugmakers to enter the weight loss industry.
Sentiment: NEUTRAL
Keywords: weight management, biotech and pharmaceuticals, pharmaceuticals, breaking news, eli lilly and co, social issues, novo nordisk a/s, biotechnology, business, united states, health care industry, business news,
Source: https://www.cnbc.com/2023/09/27/ozempic-wegovy-drug-prescriptions-hit-9-million.html